# V1 Empirics Check — deepseek/deepseek-v3.2 (Variant A)

**Model:** deepseek/deepseek-v3.2
**Variant:** A
**Date:** 2026-03-30T11:15:07.244686

---

### **Referee Report**

**Paper:** "The Competitive Flood: Distributor Market Structure and the Geography of Opioid Supply"

**Author(s):** APEP Autonomous Research

---

### 1. Idea Fidelity

The paper executes the original idea with high fidelity. It faithfully implements the core elements outlined in the Idea Manifest:
*   **Research Question:** It investigates the causal effect of pharmaceutical distributor market concentration (HHI) on county-level opioid pill supply, exactly as proposed.
*   **Data:** It utilizes the DEA ARCOS transaction database (178 million records, 2006-2012) to construct county-year distributor HHI and pills-per-capita outcomes, matching the manifest.
*   **Identification Strategy:** It employs the specified shift-share (Bartik) instrumental variable, leveraging national distributor mergers (McKesson-D&K, Cardinal-Kinray, AmerisourceBergen consolidation) as exogenous "shifts" applied to pre-period (2006) county distributor "shares."
*   **Novel Contribution:** The paper correctly positions itself as the first to open the pharmaceutical supply-chain "black box" to study the role of distributor market structure, a gap noted in the manifest.
*   **Secondary Outcomes:** It includes the planned analysis of overdose mortality from CDC WONDER data.

The paper’s central, counterintuitive finding—that increased concentration *reduces* pill supply—directly engages with the manifest's motivating question: "did market power actually cause differential supply?" No key elements from the manifest are missed.

### 2. Summary

This paper provides the first causal evidence on how the market structure of pharmaceutical distributors affected the geographic dispersion of prescription opioids. Using exhaustive transaction data and an innovative shift-share IV design based on national mergers, it finds that more concentrated local distributor markets led to *lower* per-capita pill shipments between 2006 and 2012, with suggestive evidence of reduced overdose mortality. The results challenge the narrative that concentrated "middlemen" fueled the crisis, suggesting instead that competitive pressures among distributors amplified volume-based oversupply.

### 3. Essential Points

The following three issues are critical and must be convincingly addressed for the paper to be publishable.

**1. The Exclusion Restriction for the Shift-Share Instrument Requires Substantially Stronger Justification.**
The validity of the IV hinges on the assumption that national merger-driven share changes are uncorrelated with county-level, time-varying unobservables affecting opioid demand. The claim that mergers were driven solely by "national wholesale market competition and logistics optimization" is asserted but not demonstrated. A major threat is that these mergers themselves may have been a strategic response to the booming opioid market (e.g., acquiring regional distributors to gain access to high-demand corridors). If so, the "shifts" would be correlated with local demand shocks, violating exogeneity.
*   **Required Action:** The authors must provide direct evidence that the timing and targets of these specific mergers were orthogonal to trends in opioid demand. This could involve: (a) showing that merger announcements were not preceded by abnormal growth in opioid shipments for the acquired firms relative to others; (b) analyzing SEC filings, investor calls, or trade press to document the stated, non-opioid-related rationales; (c) demonstrating that pre-trends in pill supply are parallel across counties with high vs. low predicted merger exposure. Without such evidence, the causal interpretation is seriously undermined.

**2. The Proposed "Competitive Flood" Mechanism Lacks Direct Empirical Support.**
The paper posits that competition increases supply because individual distributors ignore the public health externality, while concentrated markets face greater regulatory scrutiny. This is a compelling narrative but remains a conjecture. The results are also consistent with other mechanisms (e.g., monopsony power of concentrated distributors vis-à-vis manufacturers, different compliance cultures of acquired firms, post-merger supply disruptions).
*   **Required Action:** The authors must test the mechanism more directly. Possibilities include: (a) Interacting the treatment with measures of DEA enforcement intensity (e.g., inspection reports, fines) to see if the supply-reducing effect of concentration is stronger where regulatory oversight is higher. (b) Using transaction-level data to test if competition increases the *number* of small shipments (suggestive of volume competition) versus concentrated markets favoring larger, bulk shipments. (c) Examining whether the effect is driven by the specific merging entities (McKesson, Cardinal) whose compliance failures are documented, versus other distributors.

**3. The Analysis Insufficiently Addresses Potential Confounding from Concurrent Opioid Policies.**
The study period (2006-2012) coincides with the rapid adoption of state-level Prescription Drug Monitoring Programs (PDMPs) and "pill mill" laws. These policies directly aimed to reduce opioid supply and prescribing, and their adoption could correlate with both local market structure and supply trends. While state-clustered standard errors account for some spatial correlation, they do not control for the differential timing of these policies across states.
*   **Required Action:** The authors must include state-year fixed effects or direct controls for the implementation and strength of PDMPs and other key state-level opioid regulations (e.g., pain clinic laws, mandatory PMP checks). If the instrument’s variation is primarily cross-sectional (across counties within a state-year), state-year FEs will absorb it. The authors should therefore show their main results are robust to the inclusion of **region-by-year** fixed effects (e.g., Census division x year) as a more flexible way to control for regional policy waves, while preserving the cross-county, within-region-year variation used for identification.

### 4. Suggestions

The following recommendations are offered to strengthen the paper.

**Identification & Instrument**
*   **First-Stage Visualization:** Plot the first-stage relationship (actual HHI vs. predicted HHI) binned by quantiles of the instrument. Show the "relevance" of the instrument visually.
*   **Dynamic First Stage:** Present an event-study graph showing how actual HHI evolves in counties with high vs. low predicted merger exposure, relative to merger years. This can help assess pre-trends and the persistence of the merger effect.
*   **Placebo Shifts:** Conduct a placebo test by randomizing the timing of the "merger shocks" or using non-opioid drug classes (where distributor competition should not affect public-health-motivated volume) to confirm the effect is specific to opioids.
*   **Clarify Shift Construction:** The description of the instrument in Equation (2) and the text is confusing. Provide a clearer, step-by-step explanation: 1) Calculate 2006 county-distributor shares. 2) Calculate national distributor shares for each year. 3) For each county-year, compute counterfactual distributor shares as: `(2006 county share) * (National share_t / National share_2006)`, then re-normalize so shares sum to 1. 4) Square and sum these counterfactual shares to get predicted HHI.

**Mechanisms & Heterogeneity**
*   **Distributor-Level Analysis:** Go beyond county-level HHI. Test if the effect is driven by the market share of the *largest* distributor or by the simple count of distributors. Does the entry or exit of a *second* distributor matter more than changes in the HHI?
*   **Pharmacy Channel:** Explore heterogeneity by pharmacy type (independent vs. chain). Independent pharmacies may rely more on a single distributor, making them more sensitive to that distributor's market power.
*   **Drug Potency:** The finding that the effect is stronger for oxycodone is interesting. Discuss whether this aligns with a "regulatory scrutiny" mechanism, as oxycodone (Schedule II) is more tightly regulated than hydrocodone (Schedule III during most of the period).

**Robustness & Presentation**
*   **Statistical Significance:** The main coefficient is marginally significant (p=0.085). Acknowledge this directly and discuss the trade-off between precision and the stability of the sign (as shown in the leave-one-out). Consider presenting the 95% confidence interval to frame the range of plausible effect sizes.
*   **Population-Weighted Results:** The population-weighted estimate (Table 5, Column 2) is insignificant and very noisy. Do not over-interpret this as "attenuation." It likely reflects a loss of precision from weighting by highly variable population. Report the effective sample size and discuss that the effect may be less precisely estimated in high-population counties.
*   **Effect Magnitude:** Contextualize the -4.2% effect size. Compare it to effect sizes from studies of other supply-side interventions (e.g., PDMPs, drug rescheduling) to assess its practical importance.
*   **Data Appendix:** Clarify the 94.6% match rate for county FIPS codes. What characterizes the unmatched 5.4% of transactions? Are they systematically from certain states or distributor types? Perform a robustness check by imputing counties (e.g., using ZIP codes) or show that results are unchanged when using only matched counties.

